Compare Novartis AG (NVS) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Simon Property Group Inc — how do they compare? Novartis AG trades at $154.71 (market cap $295.37B), while Simon Property Group Inc trades at $219.28 (market cap $71.03B). The key difference: Novartis AG is far larger — about 4.2× Simon Property Group Inc's market cap, and Simon Property Group Inc pays the higher dividend (4.05%). Which is the better fit depends on your goals.
| NVS | SPG | |
|---|---|---|
Market Cap | $295.37B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $168.62 | $236.70 |
52-Week Low | $119.31 | $169.22 |
Enterprise Value | $336.69B | $99.48B |
Dividend Yield | 3.07% | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $152.41, down 2.79% today, with technical indicators showing neutral momentum near key support at $152. The company reported strong Q2 2026 earnings that beat expectations, driven by oncology drug performance, while maintaining a robust 22.5% net margin and $56.7B in revenue. Recent institutional buying activity and a predominantly Hold analyst consensus reflect cautious optimism amid patent expiration headwinds.
The outlook balances strong fundamentals and pipeline progress against generic competition risks. Investment appeal lies in dividend stability and new drug growth, though Entresto sales decline and U.S. pricing pressures require monitoring. The stock presents a defensive opportunity with moderate upside potential if newer therapies continue outperforming.
Simon Property Group (SPG) trades at $220.31, down 0.11% on the day, with a bearish technical signal as price tests support near $218. The company reported strong Q2 2026 FFO of $3.29 per share, beating estimates, and raised full-year guidance, driven by robust leasing and retailer sales growth. Financials show high profitability with a net income margin of 66.57% and ROE of 135.7%, though valuation ratios like P/S of 10.29 and P/B of 16.16 appear elevated.
Outlook remains positive with analyst consensus favoring a Buy rating and a $226.58 price target, supported by operational strength and dividend reliability. Key risks include high leverage with $24.21B in long-term debt and sensitivity to interest rates. Earnings growth and strategic acquisitions present upside, but macroeconomic headwinds could pressure retail real estate demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
